Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Qi, Hai-yan"" wg kryterium: Autor


Tytuł :
Kang-ai Injection (康艾注射液) Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway
Autorzy :
Zheng, Chun-leiAff1, Aff2, Aff3
Hou, Ke-zuoAff1, Aff2, Aff3
Wang, An-qiAff1, Aff2, Aff3
Fang, Wan-xiaAff1, Aff2, Aff3
Yu, Shi-tongAff1, Aff2, Aff3
Liang, Jin-eAff1, Aff2, Aff3
Qi, Hai-yanAff1, Aff2, Aff3
Qu, Xiu-juanAff1, Aff2, Aff3
Liu, Yun-pengAff1, Aff2, Aff3
Che, Xiao-fangAff1, Aff2, Aff3
Pokaż więcej
Źródło :
Chinese Journal of Integrative Medicine. :1-7
Czasopismo naukowe
Tytuł :
The influence of a subduction component on magmatism in the Okinawa Trough: Evidence from thorium and related trace element ratios
Autorzy :
Guo, Kun
Pokaż więcej
Źródło :
In The Structures and Processes of Subduction Zones, Journal of Asian Earth Sciences 1 September 2017 145 Part A:205-216
Czasopismo naukowe
Tytuł :
Study on Customer Satisfaction of Express Enterprises Based on AHP-FCE.
Autorzy :
Qi, Hai-yan
Zheng, Jiang-bo
Pokaż więcej
Źródło :
19th International Conference on Industrial Engineering & Engineering Management (9783642372698); 2013, p855-864, 10p
Książka
Tytuł :
Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway.
Autorzy :
Zheng CL; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Hou KZ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Wang AQ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Fang WX; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Yu ST; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Liang JE; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Qi HY; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Qu XJ; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Liu YP; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.
Che XF; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. .; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. .; Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China. .
Pokaż więcej
Źródło :
Chinese journal of integrative medicine [Chin J Integr Med] 2020 Jul 09. Date of Electronic Publication: 2020 Jul 09.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies